{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:11Z","timestamp":1789477511959,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01589-6","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:10:47Z","timestamp":1789474247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Induction FLOT Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in the Treatment of Lower Esophageal and Proximal Gastric Adenocarcinoma: A Phase II, Single-Arm Clinical Trial"],"prefix":"10.1007","volume":"57","author":[{"given":"Seyed Amir","family":"Aledavood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Pishevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Anvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Emadi Torghabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Alireza","family":"Javadinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soudeh","family":"Arastouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sare","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"22","key":"1589_CR1","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384.","journal-title":"N Engl J Med"},{"issue":"3","key":"1589_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10120-014-0403-x","volume":"18","author":"M Moehler","year":"2015","unstructured":"Moehler M, Baltin CT, Ebert M, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18(3):550\u201363.","journal-title":"Gastric Cancer"},{"issue":"7","key":"1589_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681\u201392.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1589_CR4","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","volume":"49","author":"U Ronellenfitsch","year":"2013","unstructured":"Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3149\u201358.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1589_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"13","key":"1589_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1589_CR7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ijc.26180","volume":"130","author":"N Homann","year":"2012","unstructured":"Homann N, Pauligk C, Luley K, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130(7):1706\u201313.","journal-title":"Int J Cancer"},{"issue":"3","key":"1589_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/bjc.2012.588","volume":"108","author":"S Lorenzen","year":"2013","unstructured":"Lorenzen S, Pauligk C, Homann N, et al. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108(3):519\u201326.","journal-title":"Br J Cancer"},{"issue":"1","key":"1589_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12032-012-0451-1","volume":"30","author":"AH Anter","year":"2013","unstructured":"Anter AH, Abdel-Latif RM. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med Oncol. 2013;30(1):451.","journal-title":"Med Oncol"},{"issue":"7","key":"1589_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12032-016-0774-4","volume":"33","author":"A Al-Fakeeh","year":"2016","unstructured":"Al-Fakeeh A, Ferri L, Mulla N, et al. A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. Med Oncol. 2016;33(7):62.","journal-title":"Med Oncol"},{"issue":"10184","key":"1589_CR11","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"4suppl","key":"1589_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2022.40.4_suppl.327","volume":"40","author":"RF Dunne","year":"2022","unstructured":"Dunne RF, Badri N, Nicolais M, et al. Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: a phase II study. J Clin Oncol. 2022;40(4suppl):327.","journal-title":"J Clin Oncol"},{"key":"1589_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1529-x","volume":"15","author":"T Leong","year":"2015","unstructured":"Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG). BMC Cancer. 2015;15:532.","journal-title":"BMC Cancer"},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"100934","DOI":"10.1016\/j.conctc.2022.100934","volume":"28","author":"CJ van der Zijden","year":"2022","unstructured":"van der Zijden CJ, Eyck BM, van der Gaast A, et al. Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: protocol of the TNT-OES-1 trial. Contemp Clin Trials Commun. 2022;28:100934.","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"1589_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ssu.2980100105","volume":"10","author":"P Hermanek","year":"1994","unstructured":"Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol. 1994;10(1):12\u201320.","journal-title":"Semin Surg Oncol"},{"issue":"2","key":"1589_CR16","first-page":"87","volume":"65","author":"LA Torre","year":"2012","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2012;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1589_CR17","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.7314\/APJCP.2015.16.7.2757","volume":"16","author":"Z Almasi","year":"2015","unstructured":"Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757\u201361.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"1589_CR18","first-page":"78","volume":"9","author":"Y Veisani","year":"2016","unstructured":"Veisani Y, Delpisheh A. Survival rate of gastric cancer in Iran: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2016;9(2):78\u201383.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"3","key":"1589_CR19","first-page":"3","volume":"9","author":"E Mohebbi","year":"2017","unstructured":"Mohebbi E, Nahvijou A, Hadji M, et al. Iran cancer statistics in 2012 and projection of cancer incidence by 2035. Basic Clin Cancer Res. 2017;9(3):3\u201322.","journal-title":"Basic Clin Cancer Res"},{"issue":"6","key":"1589_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MAJ.0000000000000476","volume":"349","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang J, Qiao X, et al. Concurrent neoadjuvant chemoradiotherapy for Siewert II and III adenocarcinoma at gastroesophageal junction. Am J Med Sci. 2015;349(6):472\u20136.","journal-title":"Am J Med Sci"},{"issue":"7","key":"1589_CR21","first-page":"868","volume":"16","author":"R Biffi","year":"2010","unstructured":"Biffi R, Fazio N, Luca F, et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010;16(7):868\u201374.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1589_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","volume":"47","author":"BH Burmeister","year":"2011","unstructured":"Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354\u201360.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1589_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851\u20136.","journal-title":"J Clin Oncol"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1748-717X-8-6","volume":"8","author":"JM Pepek","year":"2013","unstructured":"Pepek JM, Chino JP, Willett CG, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol. 2013;8:6.","journal-title":"Radiat Oncol"},{"issue":"24","key":"1589_CR25","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1589_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10434-001-0519-1","volume":"8","author":"AM Lowy","year":"2001","unstructured":"Lowy AM, Feig BW, Janjan N, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8(6):519\u201324.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1589_CR27","doi-asserted-by":"publisher","first-page":"e7473","DOI":"10.5812\/ijcm.7473","volume":"10","author":"SA Aledavood","year":"2017","unstructured":"Aledavood SA, Shahid Sales S, Anvari K, et al. Evaluation of tumor resectability rate and pathologic response to preoperative concurrent chemoradiotherapy in locally advanced proximal gastric and esophagogastric junction adenocarcinomas: a clinical trial. Int J Cancer Manag. 2017;10(5):e7473.","journal-title":"Int J Cancer Manag"},{"issue":"2","key":"1589_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.radonc.2007.01.009","volume":"82","author":"J Wydma\u0144ski","year":"2007","unstructured":"Wydma\u0144ski J, Suwinski R, Poltorak S, et al. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiother Oncol. 2007;82(2):132\u20136.","journal-title":"Radiother Oncol"},{"issue":"12","key":"1589_CR29","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1589_CR30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384.","journal-title":"N Engl J Med"},{"issue":"3","key":"1589_CR31","first-page":"256","volume":"12","author":"SA Aledavood","year":"2021","unstructured":"Aledavood SA, Anvari K, Shahidsales S, et al. Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: a clinical trial. Casp J Intern Med. 2021;12(3):256\u201362.","journal-title":"Casp J Intern Med"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2021.03.025","volume":"150","author":"HH Yoon","year":"2021","unstructured":"Yoon HH, Ou FS, Soori GS, et al. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021;150:214\u201323.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1589_CR33","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/annonc\/mdt339","volume":"24","author":"J Ajani","year":"2013","unstructured":"Ajani J, Xiao L, Roth J, et al. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013;24(11):2844\u20139.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"1589_CR34","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1200\/jco.2015.33.15_suppl.4002","volume":"33","author":"D Alderson","year":"2015","unstructured":"Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol. 2015;33(15_suppl):4002.","journal-title":"J Clin Oncol"},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1477-7819-9-110","volume":"9","author":"ZY Li","year":"2011","unstructured":"Li ZY, Shan F, Zhang LH, et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol. 2011;9:110.","journal-title":"World J Surg Oncol"},{"issue":"8","key":"1589_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.gassur.2003.09.007","volume":"7","author":"SG Marcus","year":"2003","unstructured":"Marcus SG, Cohen D, Lin K, et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg. 2003;7(8):1015\u201323.","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"1589_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/00365521.2021.1966092","volume":"56","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tian Z, Zeng J, et al. Effect of neoadjuvant treatment combined with radical gastrectomy on postoperative complications and prognosis of gastric cancer patients. Scand J Gastroenterol. 2021;56(11):1343\u20138.","journal-title":"Scand J Gastroenterol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01589-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:10:49Z","timestamp":1789474249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01589-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved on 01\/06\/2021 by the Institutional\/Regional Ethics Committee of Mashhad University of Medical Sciences under the title\n                      \u201cEvaluation of Tumor Clearance and Pathological Response Using Induction FLOT Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in the Treatment of Locally Advanced Adenocarcinoma of the Gastroesophageal Junction and Proximal Stomach\u201d\n                      (Project No. 991155) with the ethics code IR.MUMS.MEDICAL.REC.1400.153. Research carried out in compliance with the Helsinki Declaration (\n                      \n                      ). Before initiation, the study protocol was registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20210706051800N1, and made publicly accessible.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before enrollment, patients were fully informed about the potential benefits and risks of participation, and written informed consent was obtained. Participation was entirely voluntary and had no impact on their diagnostic or therapeutic management.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT (GPT-5) was used for language polishing and grammar correction. All scientific content, data interpretation, and conclusions were prepared and verified by the authors.","order":3,"name":"Ethics","label":"Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}